ProKidney (PROK) to Release Quarterly Earnings on Friday

Key Points

• ProKidney (NASDAQ:PROK) is set to announce its Q2 2025 earnings on Friday, August 8th, with analysts forecasting a loss of ($0.14) per share.
• In their last earnings report, ProKidney reported a loss of ($0.13) per share, outperforming expectations by $0.03, with revenue of $0.23 million.
• Analysts have mixed ratings for ProKidney, with recent upgrades from several firms raising price targets, while Bank of America downgraded the stock from "neutral" to "underperform".

ProKidney (NASDAQ:PROK - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

ProKidney (NASDAQ:PROK - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $0.23 million for the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProKidney Trading Up 1.8%

NASDAQ:PROK traded up $0.05 on Friday, hitting $2.82. 1,319,247 shares of the company's stock traded hands, compared to its average volume of 38,086,264. ProKidney has a 1 year low of $0.46 and a 1 year high of $7.13. The firm has a 50-day moving average price of $1.78 and a 200-day moving average price of $1.33. The company has a market cap of $825.41 million, a PE ratio of -4.70 and a beta of 1.26.

Analyst Ratings Changes

Several equities analysts have weighed in on PROK shares. UBS Group lifted their target price on ProKidney from $4.00 to $8.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Citigroup reiterated a "buy" rating and set a $9.00 price target (up from $6.00) on shares of ProKidney in a report on Wednesday, July 9th. Guggenheim reiterated a "buy" rating and set a $7.00 price target (up from $6.00) on shares of ProKidney in a report on Monday, July 14th. Wall Street Zen upgraded ProKidney from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Bank of America lowered ProKidney from a "neutral" rating to an "underperform" rating and reduced their price target for the company from $3.00 to $1.00 in a report on Monday, June 30th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, ProKidney currently has an average rating of "Hold" and a consensus price target of $6.25.

Insiders Place Their Bets

In related news, insider Darin J. Weber sold 103,480 shares of the business's stock in a transaction that occurred on Tuesday, July 8th. The stock was sold at an average price of $3.02, for a total value of $312,509.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 41.49% of the company's stock.

Institutional Investors Weigh In On ProKidney

An institutional investor recently raised its position in ProKidney stock. AQR Capital Management LLC boosted its holdings in ProKidney Corp. (NASDAQ:PROK - Free Report) by 106.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 52,570 shares of the company's stock after buying an additional 27,098 shares during the period. AQR Capital Management LLC's holdings in ProKidney were worth $46,000 as of its most recent SEC filing. Institutional investors and hedge funds own 51.59% of the company's stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.